The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 15, 2021

Filed:

May. 09, 2016
Applicant:

Swedish Orphan Biovitrum Ag, Basel, CH;

Inventors:

Cristina de Min, Geneva, CH;

Walter Ferlin, Geneva, CH;

Fabrizio De Benedetti, Geneva, CH;

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/24 (2006.01); G01N 33/68 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/249 (2013.01); A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); G01N 33/6863 (2013.01); A61K 39/395 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); G01N 2333/521 (2013.01); G01N 2800/24 (2013.01); G01N 2800/7095 (2013.01);
Abstract

Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFNγ, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFNγ, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFNγ) signaling, including neutralizing anti-IFNγ antibodies.


Find Patent Forward Citations

Loading…